No Data
No Data
No Data
Telix Pharmaceuticals Price Target Raised 35% to A$20.70/Share by Jefferies
Telix Pharmaceuticals Price Target Raised 35% to A$20.70/Share by Jefferies
Why Is the Telix Pharmaceuticals Share Price Frozen Today?
Up 63% so far in 2024, the Telix Pharmaceuticals Ltd (ASX: TLX) share price isn't going anywhere today.
Telix, a nuclear medicine company, announces IPO with a 100-fold increase in the past 7 years.
On June 5th, Telix Pharmaceuticals, a biopharmaceutical company focusing on radiopharmaceutical coupling drugs (RDC), disclosed the terms of its initial public offering (IPO) and plans to list on Nasdaq.
Telix Pharmaceuticals Launches $200 Million IPO in US
Telix Pharmaceuticals (TLX) said Wednesday it has launched an initial public offering in the US of 17 million American depositary shares, each representing one ordinary share, for expected gross proce
Australian biotechnology company Telix Pharmaceuticals (TLX.US) plans to IPO with a price of $11.87, raising $202 million.
Telix Pharmaceuticals plans to issue 17 million American Depositary Shares at a price of $11.87 per share (converted from its latest closing price on the Australian Securities Exchange) to raise $202 million.
Telix, Radiopharmaceuticals Maker, Sets Terms for $232M US IPO
No Data